News

The company said that a six-month review period has been assigned for the Lemtrada sBLA and it expects FDA action on this in the fourth quarter. The sBLA

The Phase I trial is designed to assess the safety, tolerability and initial efficacy of altiratinib in these patients. In preclinical studies, altiratinib has been shown to exhibit

Current Heel Inc. products will be available to USA distributors through August 2014, and to retailers and medical practitioners through December 2014. "We remain committed to serving the

"Sangamo’s powerful and precise ZFN-mediated genome editing technology allows us to modify a patient’s own stem cells and perform ‘autologous’ transplants, with the potential to replicate the functional

ADCs are monoclonal antibodies engineered to go unnoticed, delivering cytotoxic drugs to cells expressing the antigen target. Cancer therapy has become the most prevalent application area, with 30

ASP7374 has been produced by a cell-culture manufacturing method employing the Baculovirus Expression Vector System (BEVS), a next-generation recombinant technology platform for manufacturing biopharmaceutical products. Protein Sciences Corporation

The company’s move from its original 7,200 square foot location in Farmingdale, New York means that it will be able to manufacture new products, create more jobs, and

The trial failed to meet the primary endpoint of improved disease free survival (DFS) compared to single agent therapy with trastuzumab. The company said that the safety profile

US subsidiary of the company Eisai Inc. is marketing the product based on having received exclusive marketing rights from Helsinn Healthcare for the US. The company said that